ArticleCardio-oncology (London, England)2026
Trends in cardiovascular mortality among lung cancer patients in the United States: a retrospective study from 1999 to 2023.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough cardiovascular disease (CVD) frequently co-occurs with lung cancer and adversely affects prognosis, the temporal patterns of CVD mortality in this patient group remain inadequately explored. We aimed to clarify trends and disparities in CVD mortality among United States (US) adults with lung cancer.
methodsUtilizing the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) spanning from 1999 to 2023 for adults aged 35 years and older, we calculated age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) per 100,000 individuals, with the AAMRs standardized to the 2000 US population. The annual percent change (APC) and average annual percent change (AAPC) were estimated using joinpoint regression analysis. In CDC WONDER, the National Center for Health Statistics assigns the underlying cause of death using standardized World Health Organization rules. Thus, we defined CVD as the underlying cause of death and lung cancer as a contributing cause based on the database's coding framework rather than investigator judgment.
resultsAmong 93,859 CVD deaths in lung cancer patients, mortality declined significantly from 1999 to 2015 (APC: - 4.70), but increased in females from 2015 to 2023 (APC: 1.73), while remaining stable in males (APC: 0.44). Males experienced a more pronounced reduction in AAMRs, decreasing from 5.39 in 1999 to 2.24 in 2023, but consistently had higher CVD mortality rates than females. During most of the study period, Non-Hispanic African American or Black (NH Black) individuals experienced the highest AAMRs, followed by NH Whites. Long-term decline in CVD mortality reversed significantly among individuals aged ≥ 85 years since 2017. Significant differences in AAPC relative to the general population were identified among the Northeast, NH Black, NH White, males, and across all age groups except for the 75-84 cohort.
conclusionsAlthough CVD mortality in the US declined from 1999 to 2023, this trend has stalled or reversed among adults with lung cancer since 2015. Ongoing disparities by sex, race, age, region, and state emphasize the urgent need for targeted interventions for these vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.